In the Margins

Valeant names hedge fund partner to board

October 26, 2015

By Forbes

Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes

 

 

Most Read

Top of the Agenda - Industry Groups
IDC's Amy Lancellotta to retire at year-end

Amy Lancellotta will retire from the Independent Directors Council at the end of this year after 13 years as managing director and a total of 30 ...